Sarepta and Roche face a regulatory setback as the EMA's CHMP issues a negative opinion on Elevidys for Duchenne muscular ...

Sarepta Therapeutics' brutal week continued Friday after European officials rejected the company's controversial gene therapy ...

Sarepta Therapeutics Inc. shares plunged after European regulators rejected its gene therapy Elevidys, intensifying scrutiny on the drugmaker after it was pressured to halt shipments of its treatment ...

The European Medicines Agency determined testing failed to prove Elevidys’ benefit and issued a negative opinion that could ...

Friday said that the European Medicines Agency has issued a negative opinion on the conditional marketing authorization for Elevidys, intended for ambulatory patients aged three to seven with Duchenne ...

US stocks advanced midday Monday, with the S&P 500 and Nasdaq Composite notching fresh all-time intraday highs, buoyed by ...

Detailed price information for Sarepta Therapeutics (SRPT-Q) from The Globe and Mail including charting and trades.

I wonder whether the framing of the liturgy itself in instrumentalizing terms may unintentionally reinscribe problematic views of the relationship between the human and more-than-human world.

The newly published Data Quadrant from Info-Tech Research Group highlights the leading PAM solutions that help organizations secure sensitive accounts and manage privileged access effectively. The ...

EU ministers gave the final green light on Tuesday for Bulgaria to adopt the euro on January 1, 2026, making it the single currency area's 21st member.